Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Feb;13(1):e70047.
doi: 10.1002/prp2.70047.

Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System

Maryann R Chapin  1 , Sandra L Kane-Gill  1   2 , Xiaotong Li  1 , Kojo Abanyie  2 , Sanya B Taneja  3 , Susan Egbert  4 , Mary F Paine  5 , Richard D Boyce  1   2   3
Affiliations
Review

Part 2: Drug Interactions Involving Cannabis Products in Persons Aged 18 and Over: A Summary of Published Case Reports and Analysis of the FDA Adverse Event Reporting System

Maryann R Chapin et al. Pharmacol Res Perspect. 2025 Feb.

Abstract

The increasing utilization of cannabis products combined with lack of data regarding potential cannabis-prescription drug interactions is concerning. This study aimed to review published case reports and FDA Adverse Event Reporting System (FAERS) spontaneous reports to assess cannabis-drug interactions in persons aged 18 and over. A literature search identified 20 case reports that were each assessed for drug interaction causality using the Drug Interaction Probability Scale. Data collected from the FAERS revealed a greater proportion of reports mentioning serious outcomes, including death, when cannabis was used concomitantly with controlled substances compared to noncontrolled substances. Fisher's exact test showed a statistically significant difference between the controlled and noncontrolled groups (p = 0.043). Overall, these findings emphasize the need for additional research and vigilant monitoring of cannabis use when combined with other medications.

PubMed Disclaimer

Conflict of interest statement

M.R.C., X.L., K.A., S.B.T., R.D.B., S.E.: has no conflict of interest or disclosures to report. S.L.K‐G. receives grant funding from the National Institute of Diabetes and Digestive and Kidney Diseases R01DK121730 and U01DK130010, the National Center for Complementary and Integrative Health U54AT008909, and the Jewish Healthcare Foundation. M.F.P. receives grant funding from the National Center for Complementary and Integrative Health and Office of Dietary Supplements (U54AT008909), National Institute of Child Health and Human Development (R01HD081299), and National Institute of General Medical Sciences (R16GM146679), and MFP is a member of the Scientific Advisory Board for Simcyp, Certara UK Limited.

Figures

FIGURE 1
FIGURE 1
Comparative description of the top 5% adverse drug reactions mentioned in spontaneous reports involving cannabis and either controlled or noncontrolled substances. Percentages do not sum up to 100% as each report may have multiple adverse drug reactions reported.
FIGURE 2
FIGURE 2
The top 5% of adverse drug reactions present in spontaneous reports that mention a noncontrolled substance and a cannabis product compared to their frequency in reports mentioning a controlled substance and a cannabis product. Percentages do not sum up to 100% as each report may have multiple adverse drug reactions reported.
FIGURE 3
FIGURE 3
The top 5% of adverse drug reactions present in spontaneous reports that mention a controlled substance and a cannabis product compared to their frequency in reports mentioning a noncontrolled substance and a cannabis product.
See this image and copyright information in PMC

References

    1. “North America Legal Cannabis Market Size Report, 2030,” accessed December 19, 2022, https://www.grandviewresearch.com/industry‐analysis/north‐america‐legal‐....
    1. “Getting Medical Marijuana in Pennsylvania. PA.Gov,” accessed April 10, 2024, https://www.pa.gov/guides/pennsylvania‐medical‐marijuana‐program/.
    1. Bansal S., Maharao N., Paine M. F., and Unadkat J. D., “Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450,” Drug Metabolism and Disposition: The Biological Fate of Chemicals 48, no. 10 (2020): 1008–1017, 10.1124/dmd.120.000073. - DOI - PMC - PubMed
    1. Bansal S., Paine M. F., and Unadkat J. D., “Comprehensive Predictions of Cytochrome P450 (P450)‐mediated in Vivo Cannabinoid‐Drug Interactions Based on Reversible and Time‐Dependent P450 Inhibition in Human Liver Microsomes,” Drug Metabolism and Disposition: The Biological Fate of Chemicals 50, no. 4 (2022): 351–360, 10.1124/dmd.121.000734. - DOI - PMC - PubMed
    1. Horn J. R., Hansten P. D., and Chan L. N., “Proposal for a New Tool to Evaluate Drug Interaction Cases,” Annals of Pharmacotherapy 41, no. 4 (2007): 674–680, 10.1345/aph.1H423. - DOI - PubMed

LinkOut - more resources